Introduction
Recurrent genetic abnormalities occur in lymphoid and myeloid leukemia.
1,2 They include chromosomal translocations, deletions and amplification of chromosomal regions, gene mutations, and overexpression of specific genes. Most recurrent fusion transcripts generated by a translocation in leukemia have demonstrated a prognostic independent value in both acute lymphoblastic (ALL) and acute myeloid (AML) Leukemias, as well as in chronic myeloid leukemia (CML). [1] [2] [3] For this reason, the identification of fusion genes is required in the routine diagnostic process of most advanced clinical protocols, either for risk stratification, for target-specific treatments and/or as markers for monitoring minimal residual disease (MRD) during treatment. [1] [2] [3] [4] [5] [6] Fusion transcripts generated from chromosomal translocations can be detected by reverse-transcriptase polymerase chain reaction (RT-PCR). 7, 8 However, a growing biological and clinical heterogeneity is present in hemato-oncological diseases, even in genetically homogeneous subgroups characterized by the same fusion transcript. There is an emerging need for detecting gene expression levels of specific genes (that is, CASP8AP2 in ALL;
8 FLT3 or WT1 in AML, 5 but other genes are emerging as relevant from gene expression profiling studies 8 ), or for detecting genomic mutations (that is, BCR-ABL, PTPN11, KIT). [9] [10] [11] While the positivity for specific fusion transcripts can be revealed by agarose gel electrophoresis, mutations, gene expression and gene copy number alterations require additional techniques, such as sequencing, real-time quantitative PCR or comparative genomic hybridization, microsatellites analysis or single nucleotide polymorphisms (SNP) arrays. In this sense, a common platform to be applied for different diagnostic purposes is highly demanded.
Several array platforms are currently under investigations to offer the possibility to identify different leukemia subgroups based on genetic features, mainly gene expression signatures. 12, 13 The Nanogen NMW 1000 Nanochip Molecular Biology Workstation (Nanogen Inc., San Diego, CA, USA) is an electronic microchip developed and successfully applied for the identification of gene mutations, 14, 15 but not for the assessment of gene expression and fusion transcripts. The main advantage of this application compared to the standard gel electrophoresis is the possibility to specifically reveal the fusion transcript identity by using an additional discriminating fluorescent probe, instead of interpreting the size of PCR bands or to sequence amplification products. The flexibility of the microelectronic chip allows the use of a variety of discriminators of different content, length or chemical composition on the same chip, thus permitting the addressing of a multiplex PCR, where products are different.
This study demonstrates, as a proof-of-principle, that this microelectronic device by Nanogen, highly effective in detecting single base mutations, 15 is also efficient in the analysis of gene expression, thus providing as a multi-purpose platform for relevant comprehensive diagnostics of hemato-oncology patients.
Materials and methods

Patients and samples
Cell lines carrying all tested fusion transcripts (Table 1) were used as positive controls and for optimization of the procedure. The study was then performed on 194 childhood ALL, 16 childhood AML and 23 acute promyelocytic leukemia (APL) cases at diagnosis, as well as 25 CML adult patients in chronic phase. All childhood ALL patients were consecutively enrolled; other cases were selected to contain a sufficient number of positive cases. Diagnosis was done according to standard criteria. All cases were previously screened by single-step RT-PCR, according to published methods. 7 The 194 ALL cases were screened for: E2A-PBX1, MLL-AF4, BCR-ABL p190, BCR-ABL p210, TEL-AML1. The 69 AML cases included 23 patients with PML-RAR fusion transcript, 11 with AML1-ETO, 5 with CBFB-MYH11; the 25 CML included adult patients treated with imatinib and positive for p210 in first PCR. The cDNA left after the standard molecular diagnostic was used for this study. Informed consent was obtained.
Multiplex RT-PCR
Total RNA was prepared by standard phenol/chloroform extraction, and its quality was determined by UV spectrometer and electrophoresis analyses in a 1% agarose gel. Extracted RNA was re-suspended in water, and kept at À80 1C until use.
Reverse transcription was performed from 1 mg RNA, according to published protocol. 7 One tenth of the cDNA (2 out of 20 ml, 0.1 mg RNA equivalent) were amplified in 25 ml of PCR reaction, containing 1X PCR buffer (Invitrogen, Carlsbad, CA, USA), 1.5 mM MgCl, 200 mM dNTPs, 1.0 U of Taq Platinum polymerase (Invitrogen), 10 mM of each primer for all fusion genes, and 5 mM of each primers for the ABL housekeeping gene. PCR cycles were as it follows: 94 1C for 30 s, and cycled at 94 1C for 30 s, 65 1C for 30 s and 72 1C for 30 s for 35 cycles, with a final extension at 72 1C for 10 min, in 9700 Thermal cycler (Applied Biosystem, Foster City, CA, USA).
Primers were designed for the following fusion transcripts: E2A-PBX1, MLL-AF4, BCR-ABL p190, BCR-ABL p210, TEL-AML1, PML-RARA, AML1-ETO and CBFB-MYH1. These Table 1 Size and sequence of oligonucleotides Multi-purpose platform for hemato-oncology diagnostics B Corradi et al primers have been designed in a way to cover the vast majority of fusion gene transcript variants in leukemia, 7 although rare alternative fusion transcripts as a consequence of new genomic breakpoints or new splicing variants could be missed.
ABL was used as a housekeeping gene, to check for the amplifiability and the quality of cDNA. 16 For the ABL transcript, in house primers were used, identical to those adopted in standard diagnostic RT-PCR since several years in our laboratory. All RT-PCR fusion transcript-specific primers were based on the sequences of the oligonucleotides developed in the context of the Biomed1 protocol, with minor modifications; either the forward or the reverse primer of each couple contained a biotin molecule at its 5 0 end. Sequences for all PCR primers for the multiplex PCR assay are detailed in Table 1 .
Two different multiplex assays were designed for ALL/CML and AML, according to the known prevalence of the different fusion genes in different diseases. ALL/CML multiplex included: E2A-PBX1, MLL-AF4, BCR-ABL p190, BCR-ABL p210 and TEL-AML1, plus ABL as a control gene; while AML-specific multiplex was designed for PML-RARA, AML1-ETO and CBFB-MYH1, plus ABL as a control gene.
To determine the sensitivity of each assay, a 10-fold serial dilution was prepared by diluting the RNA from each fusion gene positive cell line in RNA from HL60 cell line.
Microelectronic arrays Device description. The Nanogen NMW 1000 Nanochip Molecular Biology Workstation (Nanogen Inc., San Diego, CA, USA) Biology Workstation consists of Loader and Reader components. 14, 17 Its specificity resides in the use of an electronic addressing to transfer any charged sample on a specific test site of a chip. The NMW 1000 microelectronic chip is 1 cm 2 , and it contains 100 tests sites (pads) in an active test site array area of 1 Â 1 mm. The biotinylated PCR product (amplicon) can be attached to the streptavidin present over the agarose layer of the BioChip (Permeation Layer). A new version of the Nanogen Workstation has recently been released, with 400 pads available, thus further implementing the workflow. 13 Briefly, in the Loader component, the purified PCR products are automatically addressed to the pads of the microarray by electronic addressing. On each pad, the biotinylated doublestrand amplicon binds to the streptavidin. The identification of all chimeric transcripts was obtained by using a combination of specific stabilizers and probes (Discriminators) that are complementary to the amplified sequence (amplicon). Binding of a Discriminator to the amplicon was then revealed by a Reporter in the Reader component. A representation of the assay is shown in Figure 1 .
Probes' design. A 'Discriminator' probe was designed for each fusion transcript (Table 1) , with the help of free programs available on the Internet (DNAmfold server (http://www.bioinfo. rpi.edu/~zukerm/rna) and OligoAnalyzer 3.0, by Integrated DNA Technologies (IDT, Coralville, IA, USA) (http://www.idtdna. com)). The 'Discriminator' is an oligonucleotide about 30 nt in length, with melting temperature above 38-40 1C and with a sequence complementary to the amplicon. Each discriminator was designed on one partner sequence, close to the breakpoint; in case in this area a tight secondary structure was predicted, a 'Stabilizer' molecule was also designed. The Stabilizer is an oligonucleotide 25-35 nt in length, with melting temperature above 60 1C, which must be designed immediately downstream to the Discriminator oligo, because it stabilizes the hybridization of the Discriminator through the base-stacking interactions between the 3 0 terminal base of the Discriminator and the 5 0 terminal base of the Stabilizer. The Discriminator determines the specificity of the chimeric transcript detection. A standard Discriminator bears a Cy3 (575 nm) or a Cy5 (670 nm) fluorophore at its end, allowing the specific detection. Alternatively, a Discriminator can be constructed with an 'Universal Tail' at its 5 0 . The 'Universal Tail' is a short sequence of 18 nt complementary to an 'Universal Reporter'. The common Universal Tail allows using a single fluorescent Universal Reporter to detect all fusion transcripts. The 'Universal Reporter' is an oligonucleotide about 18 nt and melting temperature of 50 1C, with a Cy3 or a Cy5 fluorophore at the 3 0 . The Universal Reporter allows to reveal the presence of a specific binding between the Discriminator and the amplicon.
Two different fluorescent Discriminator oligonucleotides were designed for the TEL-AML1 fusion transcript (on AML1 exons 2 and 3, respectively), allowing to recognize the presence of either the short, the long or both TEL-AML1 fusion transcripts associated with t(12;21). 7 Similarly, two different Discriminator oligonucleotides were also designed for the BCR-ABL fusion transcripts, with different Universal Tails, allowing to recognize the presence of p190 or p210 BCR-ABL fusion transcripts associated with t(9;22). 7 All primers, discriminators, universal tails and stabilizers were synthesized by IDT and purified by reversed-phase HPLC.
Hybridization procedure. After amplification, PCR samples are desalted by using a Multiscreen-PCR plate (Millipore, Billerica, MA, USA), and loaded in a 96-well plate (Loader plate). In the Loader, the purified PCR products are automatically addressed to the pads of the microarray by electronic addressing. On each pad (Test Site), the biotinylated doublestrand amplicon binds to the streptavidin. Each sample was loaded in duplicate on two different test sites. Two pads per chip were addressed only with L-histidine 50 mM, as a background control. After addressing and binding, all samples were denaturated with NaOH 0.3 N in order to remove the nonbiotinylated amplicon strand.
After rinsing the NanoChip with 100 ml of high-salt buffer (HSB: 50 mmol l À1 sodium phosphate, pH 7.4 and 500 mmol l À1 NaCl), 100 ml of the fusion-specific Discriminator (50 mM) were manually loaded over the chip array; if required (see Table 1 ), 50 mM of Stabilizer was also added. Then, the chip was incubated for 3 min at room temperature, then rinsed with HSB and transferred in the Reader compartment for scanning the specific fluorescence. All fusion-specific mixes were serially applied to each chip. After application of the first probe, a positive current was applied to the used pads; then three washes with low salt buffer (50 mM sodium phosphate, pH 7.0) were performed. This procedure removes discriminator, stabilizer and universal reporter, allowing a second hybridization to be performed. This protocol was repeated for each hybridization. Probes have been applied in different orders, without any effect on the sensitivity. Six serial probings were applied for ALL and four for AML.
Fluorescence detection and interpretation of results . Quantitative analysis of the hybridization results was performed by using a dedicated software accessed through Internet. Microchips were scanned after each cycle of specific hybridization, according to the defined optimal protocol (see Results). The software normalized the values by subtracting the value of background (value of the Test Sites with only L-Histidine) from the value of each sample. The software considers a signal-to-noise ratio of 5:1 as a default significant value. Accordingly to this cutoff, all pads with a signal-to-noise ratio less than 5:1 were not significant, and thus considered as negative.
Positive were pads with a signal-to-noise ratio more than 5:1. All samples were analyzed in duplicate, after being addressed to two different pads. The mean value from the two pads was considered by the software. The whole process takes about 4 h per chip.
Summary of workflow. We describe herewith the approach for a typical sample to be tested at diagnosis of leukemia for several candidate fusion transcripts. The cDNA from the diagnostic RNA serves as a template in a multiplexed PCR reaction. The multiplex PCR product is addressed to a specific pad on the NanoChip. Samples from different patients to be tested at once can be addressed to different pads and tested altogether. The stabilizer and discriminator for each target included in the multiplex are applied one after the other, with washing and reading steps in-between. In practice, for example, if a certain sample was positive for t (12;21) , then the pad corresponding to that specific sample would allow binding of the TEL-AML1-specific discriminator. At this step, after stringent washing, specific fluorescence would be read by the system, indicating TEL-AML1 positivity for that patient. Multi
Results
We developed a rapid assay to screen for the most common fusion gene transcripts in human leukemia, which combines a multiplex RT-PCR approach with the electronic hybridization and fluorescent detection on the Nanogen NanoChip Molecular Biology Workstation.
Optimization of multiplex RT-PCR
Two distinct multiplex RT-PCR reactions were designed and tested for specific fusion gene transcripts in ALL/CML or AML, respectively. The specificity of the multiplex PCR protocol was firstly tested on RNA from cell lines carrying the chimeric transcripts for all the translocation to be determined (Table 1) . Although multiplex RT-PCR was designed to be applied on the Nanogen system, with a specific fluorometric detection, gel electrophoresis has been performed to verify the presence and the correct size of amplification products (data not shown).
The first attempt of using 10 mM concentration for each primer revealed consistent results on preliminary tests on cell lines, thus this concentration was accepted as the optimal.
Both multiplex RT-PCR reactions contained primers to amplify ABL as a housekeeping gene, to be used as a control for the quality of the cDNA preparation. The ABL primers concentration was decreased to 5 mM, in order to reduce the competition with other PCR products. Overall, the ABL amplification was not visible both on gel electrophoresis and on the electronic array in 19 out of 258 cases (7.4%).
Optimization of fusion transcripts detection on the Nanogen system
After purification, any PCR amplification product was addressed and bound to the selected pads of the chip and sequentially hybridized with the discriminator probes corresponding to the different fusion transcripts to be tested. Chips were scanned for both red and green fluorochromes, corresponding to the alternative fusion transcripts in t(12;21) and t(9;22). For the other fusion transcripts, the universal reporter was applied after any single hybridization to reveal the presence of the specific amplification product.
Cell lines. For all the translocations, as well as for the control gene, it has been necessary to empirically determine the optimal thermal stringency and the number of washes required to remove any nonspecific fluorescent signal on the pad. The background was referred as the signal generated in pads with L-Histidine only. For each fusion transcript, a specific Reader files protocol was generated (Table 2) , consisting of the thermal stringency (washing temperature), the specific number of washes of the NanoChip with the HSB, necessary to remove the nonspecific binding, and the intensity of the fluorescent gain on the scanner software.
For ABL, PML-RARa and CBFB-MYH11, chips were scanned after each wash at medium photomultiplier tube (PMT) gain, with an accumulation value of 256 as default settings for the laser; for E2A-PBX1, MLL-AF4, AML1-ETO and TEL-AML1, the PMT gain was high and the accumulation time automatic; for BCR-ABL, the red and green fluorescence were both acquired at high PMT gain and with accumulation time of 128 ms.
Sensitivity tests
To test the sensitivity of each assay, 10-fold serial dilutions of target cDNA in cDNA from HL60 cell line were performed and hybridized on the chip. In Table 3 , the sensitivity reached for each fusion transcript detection is indicated, ranging from 1:100 to 1:10 000. Probes have been applied in different orders, without any effect on the sensitivity. Probes have been applied in different orders, without any effect on the sensitivity. We performed six serial probings for ALL and four for AML, without sensitivity effects. Other authors 18 used a multiplex approach with 24 serial probings. This information has been included into the revised version. Figure 2 shows an example of sensitivity tests for the BCR-ABL p210 transcript.
Patients' samples analysis
The summary of the overall results is presented in Table 3 .
Acute lymphoblastic leukemia. The multiplex RT-PCR for ALL allowed the detection of the following fusion transcripts: BCR-ABL p190, BCR-ABL p210, MLL-AF4, TEL-AML1 and E2A-PBX1. Among 194 childhood ALL patients analyzed, 2 were positive for BCR-ABL p210, 3 for BCR-ABL p190, 27 for TEL-AML1, 2 for MLL-AF4 and 9 cases were positive for E2A-PBX1 (Table 3) .
All these patients were screened in the routine setting by 'single PCR' for all the fusion transcripts listed, according to published protocols. 7 The analysis with the Nanogen system was done blinded. None single discrepancy was observed in results, being all positive results by Nanogen also positive in standard PCR, as well as the negative cases. Figure 3 shows a representative result on the Nanogen system for TEL-AML1 (panel A) and BCR-ABL (panel B).
By contrast, 10 samples positive for one of the translocations resulted negative for the ABL gene in the first analysis. For these cases, we performed a 'single' RT-PCR for the ABL control gene and re-addressed the PCR product on the chip, after desalting. In all the 10 cases we then obtained a fluorescent signal, indicating positivity.
Acute myeloid leukemia. The multiplex RT-PCR for AML allowed the detection of the following fusion transcripts: PMLRARa, AML1-ETO and CBFB-MYH11. A total of 23 APL cases were positive for PML-RARa fusion transcript (Table 3) . Among 46 childhood AML (non-APL) patients analyzed, 11 were positive for AML1-ETO and 5 for CBFB-MYH11; a single discrepancy was observed in results, represented by one sample positive for t (8;21) in singleplex PCR and negative by the NanoChip. 
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia.
Multi-purpose platform for hemato-oncology diagnostics B Corradi et al Chronic myeloid leukemia. A total of 25 adult CML patients at the first presentation were tested on the Nanogen system. All cases were positive for the BCR-ABL p210 fusion transcript. None single discrepancy was observed in results, being all positive results by Nanogen also positive in standard PCR, as well as the negative cases (Table 3 ). Figure 3 shows a representative result on the Nanogen system for BCR-ABL (panel b).
As for the ALL, nine of these CML cases produced no-call for the ABL gene control, but they resulted positive after repeating the 'single PCR' for ABL.
Discussion
We herewith presented the proof-of-principle of using the combination of multiplex RT-PCR and active electronic microarray technology to detect fusion transcripts in leukemia patients.
Translocation-derived fusion transcripts have prognostic relevance in leukemia, and they represent PCR targets for detection of residual disease during treatment. For these reasons, the detection of main recurrent fusion transcripts is required in all advanced treatment protocols for correct patients stratification according to relapse risk. In this paper, we focused on the most frequent and prognostically relevant translocations in ALL/CML (t(1;19), t(4;11), t(9;22) and t(12;21), coding for the E2A-PBX1, MLL-AF4, BCR-ABL and TEL-AML1 fusion genes, respectively) 2, 3, 7 and AML (t(15;17), t(8;21) and inv (16) , coding for the PML-RARA, AML1-ETO, CBFB-MYH11 fusion genes, respectively). 1, 7 In a total of 288 patient samples, blindly and sequentially analyzed, we found high concordance between the routine, highly standardized procedure such as singleplex RT-PCR 7 and the new multiplex RT-PCR/electronic microarray technology. The sensitivity of fusion transcript detection (from 10 À2 to 10
À4
according to the specific transcript) could be related either to the actual expression level of each target transcript, and/or to the used chemistry. This sensitivity was largely compatible with the diagnostic requirement, higher than the limits of morphological examination, and in the same range of a singleplex, single-step PCR. 7 The fusion transcript detection is robust, as we did not observe any difference in term of quality and sensitivity in serial chips, even from different batches. Although we did found samples positive for t(9;22) fusion transcripts being negative for ABL gene in the multiplex approach, however, this result does not compromise the detection of fusion transcripts, and all samples were positive when re-tested in singleplex PCR for ABL gene. We suppose that, with the chemistry used in the multiplex PCR, a competition between reagents makes the PCR for BCR-ABL more efficient than the ABL amplification. This apparent disadvantage, which occurs in most multiplex-PCR approaches, should be further investigated to find optimal conditions for all targets; however, this technical aspect does not affect the major aim of this paper, focused on demonstrating the feasibility of detecting leukemia-specific fusion transcripts in the multipurpose Nanogen platform. One possibility would be to modify the ABL test or to include a different control gene, according to the guidelines for designing appropriate control gene assays, as described in Ref. 16 Active electronic microchip array technology improves selectivity and allows rapid discrimination of different fusion transcripts. The electronic addressing allows selective and rapid transport of DNA molecules by charge, with a concentration effect; while the electronic hybridization increases the efficiency of the reaction by both facilitating strand separation of target DNA in a low-ionic-strength environment and by providing electronic stringency control. 14, 17 While applying the standard RT-PCR approach, one has only to rely on the size of PCR bands on gel electrophoresis (according to a molecular weight marker and positive controls), or, to be more confided, the nucleotide sequence must be obtained. One major advantage of the presented application is to apply a sequence-based discriminating fluorescent probe to specifically reveal the fusion transcript identity, thus sparing from gel electrophoresis and sequencing. Both systems are qualitative, not quantitative; in this sense, the proposed approach cannot be used for MRD monitoring, where the precise quantification of aberrant transcripts is required. In that context, qRT-PCR remains the reference method, 19 directed to specific transcripts detected at diagnosis. Moreover, the multiplex approach presented here was not intended to be exhaustive for all possible fusion transcript variants in leukemia. We limited to the most frequent and prognostically relevant translocations; 7 however, more extensive multiplex RT-PCR methods 20 could potentially be incorporated in this approach, which allows the combination of multiplex-PCR and multiple probings, 18 with different fluorescent probes. Indeed, we would like here to underline the availability of this innovative platform which allows the contemporary performance of multiple genetic analyses, including SNP and mutation detection, gene expression profiling, as well as splicing isoform detection. [21] [22] [23] In hemato-oncology, as well as in other diseases, there is a growing interest in integrating gene expression profiling, SNP array genotyping and mutation detection for a comprehensive approach to patient classification. For this purpose, information from many different types of genetic analyses needs to be combined. For example, specific mutations of the ABL gene in BCR-ABL positive patients confer resistance to imatinib, while they can be treated with efficacy with alternative drugs. 24 Moreover, it has been demonstrated that KIT mutations confer poor prognosis to core binding factor leukemias; 11 by contrast, JAK2 mutations can be monitored in PhÀ myeloproliferative disorders, polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis. 25 Even more relevant, AML patients with specific cytogenetic findings or with normal karyotype can be further subdivided into prognostic categories based on the presence or absence of particular gene mutations or changes in gene expression. Importantly, many of these molecular genetic alterations constitute potential targets for risk-adapted therapies.
26 NPM1 mutations were revealed as the most recurrent aberration in AML, with type A, C and D covering 85-90% of cases. 26 The presence of this mutation is higher in AML cases with normal karyotype, and it is associated with good prognosis in cases negative for FLT3 mutations. CEBPA and AML1 point mutations are also recurrent mutations in AML cases with normal karyotype. 26 All these different type of genetic aberrations can potentially be included in a unique AML-dedicated electronic array, thus ensuring the contemporary assessment of aberrations peculiar of patients' subgroups. By contrast, mutations variable in sequence and length, such as FLT3-ITD or MLL-PTD 26 cannot be detected by this approach. In principle, the feasibility of detecting gene expression combined with the improvement of the quantification could also allow the inclusion on the same array of genes whose expression can be prognostically relevant, such as WT1, ERG, BAALC or FLT3.
26
Although genome-wide, high-density microarray technology is extremely valuable for global gene expression profiling of patients in a preclinical setting, data from such experiments typically lead to identification of a subset of most informative targets. The subsequent validation of these targets and the use of a panel of the validated genes as a diagnostic tool require a platform that enables rapid analysis of a limited number of specific targets of interest. Currently available methodologies are not, however, well suited to analysis of small subsets of targets. Indeed, we showed that the electronic hybridization enables multiplexed gene expression analysis, and it can be performed in as little as 5 h. Moreover, the protocol requires relatively small quantities of total RNA, consistent with monitoring expression patterns in limited patients samples.
Although the cost of the proposed procedure is higher than the standard multiplex-PCR/gel electrophoresis for the fusion transcripts, the inclusion of different test on the same array allows to decrease the costs drastically. To increase the workflow and further reduce the costs, because conditions favorable for hybridization occur only at those array site(s) that are electronically activated, the same set of target genes from different sample sources can be monitored on a single microarray, using sequential electronic hybridizations. Such control represents a particular strength of electronic microarray hybridization for gene expression monitoring, allowing additional flexibility in assay configuration while reducing experimental variation arising from between-chip comparisons.
Furthermore, the open architecture of the electronic microarray enables flexibility in assay design; as long as additional molecular markers became medically relevant, those targets can be easily incorporated into the analysis.
In conclusion, we presented here the use of electronic microarray hybridization to perform accurate and reproducible multiplex RT-PCR detection of fusion transcripts in leukemia.
We discussed the potential use of the electronic microarray technology in the hemato-oncology setting because of its ability to perform multiple genetic analyses on a single microarray, by confining different assays to specific subsets of array sites. The new version of the NanoChip platform (Nanogen NanoChip 400) 13 increased the number of available test sites (400 instead of 100), which in addition to further modifications, improved the performance and decreased the costs of the system.
